Zhu Yang, Matsumura Yasumoto, Wagner William R
McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, 15219, USA; Department of Bioengineering, University of Pittsburgh, Pittsburgh, PA, 15219, USA.
McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, 15219, USA.
Biomaterials. 2017 Jun;129:37-53. doi: 10.1016/j.biomaterials.2017.02.032. Epub 2017 Mar 1.
Intramyocardial biomaterial injection therapy for myocardial infarction has made significant progress since concept initiation more than 10 years ago. The interim successes and progress in the first 5 years have been extensively reviewed. During the last 5 years, two phase II clinical trials have reported their long term follow up results and many additional biomaterial candidates have reached preclinical and clinical testing. Also in recent years deeper investigations into the mechanisms behind the beneficial effects associated with biomaterial injection therapy have been pursued, and a variety of process and material parameters have been evaluated for their impact on therapeutic outcomes. This review explores the advances made in this biomaterial-centered approach to ischemic cardiomyopathy and discusses potential future research directions as this therapy seeks to positively impact patients suffering from one of the world's most common sources of mortality.
自10多年前概念提出以来，心肌内生物材料注射疗法在治疗心肌梗死方面取得了重大进展。前5年的阶段性成功和进展已得到广泛综述。在过去5年中，两项II期临床试验报告了其长期随访结果，许多其他生物材料候选物已进入临床前和临床试验阶段。近年来，人们还对生物材料注射疗法相关有益效果背后的机制进行了更深入的研究，并评估了各种工艺和材料参数对治疗结果的影响。本综述探讨了这种以生物材料为中心的缺血性心肌病治疗方法所取得的进展，并讨论了该疗法在寻求对全球最常见死亡原因之一的患者产生积极影响时未来潜在的研究方向。
